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doi:10.1016/j.asjsur.2011.08.007Summary Objective: We evaluated the efficacy and outcome of laser photoselective vapor-
ization of prostate (PVP) in patients with voiding difficulty due to prostatic obstruction induced
by advanced prostate cancer (PC).
Methods: We retrospectively studied the records of 13 patients with advanced PC and prostatic
obstruction with a mean prostate volume of 65.0 ml. All of the 13 patients received PVP between
2006 and 2010 due to the symptoms of voiding difficulty or acute urinary retention (AUR; NZ 10)
refractory to medical treatment. Perioperative safety and functional results were evaluated.
Results: Lasering time ranged from 24 to 20 minutes (mean 67  26), during which 66e423 KJ
(mean 172  95) of laser energy was delivered. All patients could resume voiding function with
a mean catheterization time of 3.0 days.
Conclusions: Our preliminary results suggest that PVP is a safe and effective procedure for
relieving prostatic obstruction without intraoperative blood transfusion, water intoxication, or
other complications in patients with advanced prostate cancer.
Copyrightª 2011, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights reserved.t of Urology, Chang Gung
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n Surgical Association. Published1. Introduction
Prostate cancer (PC) is a relatively common cancer in older
men. Radical prostatectomy and definitive therapy is
usually applied to younger patients with localized disease.
However, in patients with metastatic disease, androgen-
suppressing strategies and active surveillance remains theby Elsevier Taiwan LLC. All rights reserved.
Table 1 Patients and disease characteristics
Variable
Patient number 13
Age at PVP (years) 76.5  8.3
Preoperative TRUS prostate
volume (ml), n Z 13
65.0  39.2
PSA at diagnosis (ng/ml) 1740  3502
(13w12498)
Stage at surgery (III/IV) 4/9
Mean Pre-PVP flow
rate (ml/s), n Z 6
5.0 (3e8)
Mean post-PVP flow
rate (ml/s), n Z 12
9.8 (6e17)
Mean laser times (minutes) 67  26 (24e120)
Mean laser energy delivered (kJ) 172  95 (66e423)
Perioperative complications N Z 8
Urinary tract infection 1
Hematuria need to irrigate 1
Failed initial TWOC 8
Failed second TWOC 3
Postoperative outcome
Successful TWOC in 1 mo 13
Time to successful TWOC (d) 3.0  1.4 (2e9)
Residual urine (ml) 85  144 (3e434)
TWOC Z trial without catheter.
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symptoms (LUTS), especially aberrant growth of prostatic
cancer induced bladder outlet obstruction, have been
increasing in men with advanced diseases, significantly
impacting their quality of life.
Transurethral resection of the prostate (TURP) has been
the standard therapy for relieving bladder outlet obstruc-
tion (BOO) due to benign prostatic hyperplasia (BPH) or PC
for more than 7 decades.1e4 Safety considerations for TURP
in men with PC still remain a major concern, both in
surgical and oncological risks.2e6 In the past decade, the
use of laser photovaporization of prostate (PVP) has
emerged as a well accepted alternative to TURP for
relieving BOO caused by BPH.7,8 PVP is considered as effi-
cacious as TURP, offering safety, low morbidity, rapid
recovery, immediate and sustained improvement, and long-
term durability.7,8 To our knowledge, there have been few
published studies regarding to the use of PVP for relieving
BOO for advanced PC patients. The purpose of this study
was to evaluate the safety and efficacy of PVP in manage-
ment of advanced PC patients with prostatic obstruction.
2. Materials and methods
We retrospectively reviewed the medical records of 343
patients with voiding difficulty who were refractory to
conventional medical treatment and treated with the 120-W
GreenLight high performance system (HPS; American Medical
Systems, Minnetonka, Minnesota, USA) for the palliation of
BOO in our department between March 2006 and January
2010. The standard procedures of PVP were similar to that
published previously by Gomez.9 According to the sixth
edition of the TNM staging system of the American Joint
Committee onCancer (2002), advancedPC is defined as either
stage III or stage IV disease.10 Patients who previously
received transurethral surgery such as TURP or urethrotomy
were excluded.
Thirteen patients with advanced PC and with refractory
voiding difficulty were treatedwith 120-WGreenLight HPS for
the palliation of BOO and were included in this study. A
thorough chart review including inpatient and outpatient
records was done. The primary diagnosis of PC was made by
transrectal ultrosonography (TRUS) guided biopsy in all
patients, and tumors were graded using the Gleason score.
Serum prostate specific antigen (PSA) was obtained from the
time of diagnosis to the end of the follow-up. Advanced PC
was diagnosed by bone scan, and/or computed tomography,
or magnetic resonance imaging. This study was approved by
our institutional review board. Given the retrospective
design, informedconsent to enter this studywas not required.
3. Results
Table 1 shows the demographic details of these patients.
Between March 2006 and January 2010, 13 patients with
a mean age of 76.5  8.3 years (60e91 years of age)
underwent palliative PVP for relieving prostatic obstruction
due to advanced PC. Ten out of the 13 patients had
a history of urinary retention and needed urethral cathe-
terization. At cancer diagnosis the mean PSA was1740  3502 (range: 38e12498) ng/ml. PVP was performed
under spinal or general anesthesia. Efficient debulking and
hemostatic effects was achieved during operation (Fig. 1).
There were no intraoperative complications or mortality.
Laser time ranged from 24 to 120 (mean 67  26) minutes.
Mean 172  95 KJ of laser energy was delivered. The mean
follow-up time was 23.4  14.1 months.
According to the grading system of complications pub-
lished by Dindo et al11 only two patients experienced grade II
complications, one had urinary tract infection, and the other
encountered blood clots needing irrigation. In addition to
these two patients, there were another six patients failing
initial trial without catheter (TWOC) 1 or 2 days after opera-
tion, which could be considered as a grade I complication.
Unlike most BPH patients who received PVP who could void 1
day after surgery, our patients took a longer time to accom-
plish TWOC (mean 3 days). However, all of our patients could
void within 1 month of the operation. In addition, 3 of 13
(23.1%) patients received repeated surgical reintervention
(TURP or re-PVP, dependent on the availability of PVP) at 2,
15, 29, and 36 months after initial PVP due to tumor bleeding
or regrowth. At the timeof the latest analysis onepatient died
from castration-resistant prostate cancer (CRPC) 38 months
after PVP and 43 months after the diagnosis of CRPC.
4. Discussion
Bothersome LUTS have been increasing in men with
advanced PC and significantly impacted their quality of life.
TURP has been the undisputed gold standard therapy for
Figure 1 (A) Preoperative computed tomography showed advanced prostate cancer with extracapsualr invasion; (B) preopera-
tive cystoscopy showed bladder outlet obstruction induced by advanced prostate cancer; (C) postoperative cystoscopy showed
relief of bladder outlet obstruction after PVP.
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In terms of surgical therapies for relieving BOO due to
BPH, PVP had proved to have the same efficacy as TURP,
while offering an established safety, low morbidity, rapid
recovery, and long-term durability.7,12 Our preliminary
results in treating patients with PC and PVP were promising,
with excellent safety outcomes and good efficacy. The
perioperative complications were relatively mild with PVP.
In our series, significant hematuria was negligible except
for one patient who needed saline irrigation. Another grade
II complication was urinary tract infection, which was
solved easily with antibiotics. No patient needed blood
transfusion nor did water intoxication happen during PVP.
TURP might cause cancer cells dissemination on locally
advanced PC.13,14 Although debates on the potential nega-
tive effect remain, TURP has also shown its association with
an increase in metastasis and death in patients with
advanced PC.4,13e15 The condition may be related to the
procedures of TURP or may be secondary to an unidentified
adverse prognostic factor associated with BOO in this subset
of patients. The 532-nmGreenLight of HPS is absorbed by the
hemoglobin and coagulated arterial and venous bleeders
with significant efficiency. This high absorption coefficient
accounted for adequate tissue vaporization and coagulation
effect on prostate tissue.7,16,17 The HPS vaporizationprovided an option for men with prostatic obstruction due to
BPH or PC.12,16 In a canine study, no irrigant absorption was
detected after PVP.17 This technique brought in not only
adequate tissue coagulation on hemostatic effect, but it also
brought the possibility to prevent tumor cell dissemination
through cutting veins as with TURP.
The functional results in our series were acceptable. The
rate of failed TWOC that needs recatheterization was high
(61.5%) when we routinely removed the catheter at post-
operative Day 1 or 2. In our series, the time to successful
catheter removal was 3.0  1.4 (2e9) days. It was longer
than 1.7w1.8  1.5 days in patients with BPH who received
PVP in other series,17,18 but was similar to Chang’s5 report
(2.69  1.01 days) in palliative TURP for patients with PC.
However, it is not a major issue in palliative surgery for
advanced PC. What we learned was to remove the catheter
1e2 days later in patients with PC than in patients with
BPH, thus all of our patients could accomplish successful
TWOC within 1 month after the operation. Compared with
a series of palliative TURP in patients with PC, Crain2
reported that 42% failed initial TWOC, there was 8.3%
recatheterization, and there was 21% chronic drainage in 19
patients. Our results are promising because all patients
achieved successful TWOC within 1 month postoperatively,
although high residual urine over 100 ml was noted in three
Table 2 Comparative data of palliative PVP and TURP
PVP Crain2,* Gnanapragasam3 Marszalek4 Chang5
Patients (N ) 13 19 46 81 14
Mean age at operation 76.5 74 72 75.9 75.8
Pre-op AUR (%) 76.9 13.0 34.8 30.0 100
Post-op RU (ml) 85  144 N N N N
Post-op UF rate ml/s 9.8 7.38 8.8 N N
Failed TWOC (%) 61.5 42 43.5 N 16.7
LTC within 1 y d 21 26.1 N N
Reoperation 23.1 29 10.9 N 28.6
Blood transfusion needed (%) 0 10.5 N 9.9 N
Peri-op mortality (<30 d), % 0 5.3* N 2.2 0
* One patient committed suicide 5 days after surgery.
LTC Z long-term urinary catheterization; N Z not shown; peri-op Z perioperative; pre-op Z preoperative; post-op Z postoperative;
RU Z residual urine.
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residual urine (>250 ml) improved after medical treatment
with Urecholine and an alpha blocker.
In the palliative TURP series, up to 29% of patients
experienced surgical reintervention for bleeding or
obstruction,2 and up to 26% of patients needed long-term
catheterization.3 A high percentage of failed initial TWOC,
a high rate of chronic catheterization, and a high residual
urine are found in patients who receive TURP,2e5 and the
same results were found in our series of PVP. The compara-
tive data of PVP and another four series of palliative TURP in
advanced PC are shown in Table 2.2e5 Risk factors of failed
initial TWOC had been postulated as a incomplete channel
creation, impaired wound healing, and general health
deterioration to patients with advanced PC. Another possi-
bility is the detrusor dysfunction, which is induced by
delayed surgical intervention. The immediate functional
results of PVP versus TURP (failed initial TWOC: 61.5% in PVP
vs. 16.7 to 43.5% in TURP; Table 2) recommend against PVP.
However, the current PVP group took advantage of safety
and showed no need for blood transfusion and no perioper-
ative mortality. Our results were in line with a randomized
clinical trial of 120 patients with BPH that demonstrated no
major intraoperative complications; none of the patients in
that study required blood transfusion in the PVP group.19
However, among TURP patients, 12 (20%) required trans-
fusion, 3 (5%) developed TUR syndrome, and capsule perfo-
ration was observed in 10 patients.19
There has been a report on the possibility of TURP in
promoting the metastasis of PC, and the result of distant
metastasis was alarmingly poor, with 38% in TURP versus
13% in needle biopsy after 5 years and 56% versus 22% after
10 years.14 With the characteristics of immediate and
efficient photoablation as well as photocoagulation in PVP,
the possibility of distant metastasis might be reduced with
long-term follow-up.
There are some limitations in this retrospective study.
Even in advanced PC, there still are a wide variety of
diseases that may prejudice prognosis of treatment, e.g.,
hormone sensitiveness and the general performance of the
patient. It is hard to determine a functional difference
without a comprehensive urodynamic study before and
after surgical intervention. The number of cases is too small
to make a good comprehensive logistic analysis. However,PVP did achieve excellent immediate efficacy and low
perioperative morbidity in patients of this disease entity.
5. Conclusions
Our preliminary results suggested that palliative PVP can be
performed safely and efficiently for relieving bladder outlet
obstruction in patients with advanced PC, and this treat-
ment offers significant improvement in a patient’s voiding
function.
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